Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
11.48B | 11.48B | 12.44B | 11.66B | 5.08B | Gross Profit |
4.12B | 3.68B | 4.15B | 3.73B | 2.09B | EBIT |
766.00M | 612.00M | 1.09B | 585.00M | 566.48M | EBITDA |
1.60B | -996.00M | -110.00M | 1.80B | 897.67M | Net Income Common Stockholders |
243.00M | -2.56B | -1.84B | 268.00M | 365.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
469.00M | 703.00M | 493.00M | 715.00M | 656.84M | Total Assets |
28.67B | 30.98B | 35.39B | 39.68B | 13.56B | Total Debt |
9.51B | 10.80B | 10.97B | 11.40B | 4.41B | Net Debt |
9.04B | 10.10B | 10.48B | 10.69B | 3.76B | Total Liabilities |
14.76B | 16.34B | 17.60B | 18.45B | 7.14B | Stockholders Equity |
13.88B | 14.61B | 17.73B | 21.12B | 6.32B |
Cash Flow | Free Cash Flow | |||
607.00M | 936.00M | -161.00M | 1.04B | 522.30M | Operating Cash Flow |
1.07B | 1.44B | 345.00M | 1.44B | 714.10M | Investing Cash Flow |
326.00M | 574.00M | 745.00M | -18.00M | -187.46M | Financing Cash Flow |
-1.61B | -1.85B | -1.18B | -1.30B | -511.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $4.02B | 31.01 | 11.87% | 1.74% | 6.30% | 41.01% | |
69 Neutral | $13.97B | 22.02 | 25.53% | 1.82% | -0.61% | 15.06% | |
68 Neutral | $8.79B | 9.71 | 16.16% | 4.36% | 2.78% | 1.50% | |
63 Neutral | $18.76B | 18.05 | 7.19% | 9.64% | -6.53% | -50.08% | |
63 Neutral | $24.64B | 18.67 | 18.47% | 2.52% | -7.67% | -0.58% | |
55 Neutral | $20.25B | 83.39 | -6.08% | 2.17% | 0.68% | 66.69% | |
49 Neutral | $1.94B | -1.23 | -21.28% | 3.73% | 1.19% | -29.73% |
On May 1, 2025, International Flavors & Fragrances Inc. held its Annual Meeting of Shareholders where ten directors were elected, PricewaterhouseCoopers LLP was ratified as the independent auditor for 2025, and executive compensation was approved. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder relations.
Spark’s Take on IFF Stock
According to Spark, TipRanks’ AI Analyst, IFF is a Neutral.
IFF’s overall stock score reflects its recovery trajectory, with improved profitability and debt management. However, the stock is currently experiencing bearish technical signals and appears overvalued, leading to a tempered outlook despite positive elements from recent earnings.
To see Spark’s full report on IFF stock, click here.
In 2025, International Flavors & Fragrances Inc. reorganized its internal structure, affecting how resources are allocated and financial performance is assessed. This led to the separation of its former Nourish segment into two new segments: Taste and Food Ingredients. The reorganization aims to align with the company’s updated operating model and improve investor transparency by recasting 2024 financial data to reflect these changes. The new reportable segments as of Q1 2025 are Taste, Food Ingredients, Health & Biosciences, Scent, and Pharma Solutions.
Spark’s Take on IFF Stock
According to Spark, TipRanks’ AI Analyst, IFF is a Neutral.
IFF’s overall stock score reflects its recovery trajectory, with improved profitability and debt management. However, the stock is currently experiencing bearish technical signals and appears overvalued, leading to a tempered outlook despite positive elements from recent earnings.
To see Spark’s full report on IFF stock, click here.
On March 12, 2025, Jennifer Johnson, the Executive Vice President, General Counsel, and Corporate Secretary of IFF, announced her resignation. She will remain with the company until July 1, 2025, to facilitate a smooth transition, and her departure is considered a qualifying event under IFF’s executive severance policy.
On February 20, 2025, International Flavors & Fragrances Inc. announced the upcoming departure of Simon Herriott, President of Health & Biosciences, effective March 31, 2025. Leticia Goncalves Lourenço will succeed him as President of the Health & Biosciences division starting March 1, 2025, marking a significant leadership change within the company.